Clinical Trials Logo

Hypertension, Pulmonary clinical trials

View clinical trials related to Hypertension, Pulmonary.

Filter by:

NCT ID: NCT03581877 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Peripheral Low Dose Thrombolysis Versus Catheter Acoustic Directed Thrombolysis for Submassive PE

Start date: July 2018
Phase: Phase 4
Study type: Interventional

To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)

NCT ID: NCT03581851 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Acute Exposure of Simulated Hypoxia on ECG and Non-invasive Blood Pressure

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by Finapres® NOVA Technology.

NCT ID: NCT03581695 Recruiting - Clinical trials for Hypertension, Pulmonary

Inflammatory Biomarkers of Pediatric Pulmonary Hypertension

Start date: June 20, 2018
Phase:
Study type: Observational

To investigate if the inflammatory protein, high mobility group box 1 (HMGB1), along with other inflammatory mediators, is elevated in pediatric patients with congenital heart disease (CHD) and pulmonary hypertension as compared to those with CHD alone, or with healthy controls.

NCT ID: NCT03579862 Recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

Identification of Heritable CTEPH

Start date: December 25, 2013
Phase:
Study type: Observational

Some patients who have blood clots come down with a life-threatening condition known as Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which is high blood pressure only in the arteries of the lungs. This study seeks to understand more about the genetics causes of CTEPH by obtaining blood samples and examining family histories.

NCT ID: NCT03576885 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia

Start date: September 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Inhaled nitric oxide (iNO) is an effective treatment for pulmonary hypertension (PH) in term and near-term infants. Preterm infants are at risk for early PH that is associated with high risk for bronchopulmonary dysplasia or death. In multiple clinical trials, iNO treatment was not effective for BPD prevention. However, infants were not screened for PH and iNO treatment was not targeted for PH. iNO treatment for PH in preterm infants is controversial due to lack of evidence. The study team hypothesizes that early diagnosis of PH (72-96 hours of life) and iNO treatment will decrease the incidence of death and bronchopulmonary dysplasia and improve oxygenation in extremely preterm infants. 1. To determine if iNO treatment of extremely preterm infants with early pulmonary hypertension as established with echocardiographic evidence at 72-96 hours of age will decrease incidence of death or BPD. 2. To determine if iNO treatment of extremely preterm infants with early PH will decrease the pulmonary artery pressure and improve oxygenation within 72 hours of intervention.

NCT ID: NCT03574675 Recruiting - Clinical trials for Pulmonary Hypertension

Acute Exposure of Simulated Hypoxia on Cardiac Output

Start date: May 2, 2018
Phase: N/A
Study type: Interventional

Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on non-invasive cardiac output assessments by Finapres® "NOVA" Technology at rest and under exercise.

NCT ID: NCT03572036 Active, not recruiting - Sickle Cell Disease Clinical Trials

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

Start date: June 26, 2018
Phase:
Study type: Observational

Background: Sickle cell disease (SCD) is a common inherited blood disorder. Many people with SCD are at risk to get pulmonary hypertension (PH). PH means that the blood pressure in the blood vessels to the lungs is high, and is a serious disease and. Very few studies have looked at the success of treatments for PH in people with SCD. Researchers want to learn more about treating PH with a type of drug called phosphodiesterase type 5 inhibitors (PDE5-I). They will look at the records of people who have already joined other studies. Objective: To identify people who already joined NIH SCD protocols whose medical records should be reviewed. The review will look at the description of SCD patients with PH who have already taken PDE5-I and the outcomes for these people. Eligibility: Adults ages 18 and older with SCD and PH. They must have joined certain NIH studies and taken PDE5-I therapy for at least 16 weeks. Design: This study is a review of medical records. Researchers will collect data from databases of existing studies. They will identify people in those studies who have SCD and PH and took the study drug for at least 16 weeks. Researchers will review the full medical records of those people. From that review, researchers will find participants who meet the inclusion criteria. They will extract data from those records. Researchers will analyze the data. This includes results from heart and lung tests, imaging, and walking tests. It will also include results of a procedure called right heart catheterization. Demographic data and lab data will also be collected. Researchers will remove identifying information from the data, then share it in a database.

NCT ID: NCT03565471 Recruiting - Clinical trials for Pulmonary Hypertension

Atrial Septal Defect - Exercise Capacity and Pulmonary Hypertension

Start date: August 1, 2018
Phase:
Study type: Observational

The purpose of the study is to compare exercise capacity, cardiac contractility, pulmonary vascular pressures and heart rate variability between patients with an atrial septal defect and healthy controls.

NCT ID: NCT03564522 Recruiting - Clinical trials for Pulmonary Hypertension

Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension

Start date: April 1, 2017
Phase:
Study type: Observational

This study looks to develop a multi-scale computational model of Pulmonary Hypertension, this clinical model will be calibrated using longitudinal, retrospectively and prospectively acquired human clinical data.

NCT ID: NCT03554291 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

REHAB-PH
Start date: July 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.